Prosperity Consulting Group LLC Buys 268 Shares of Danaher Co. (NYSE:DHR)

Prosperity Consulting Group LLC boosted its stake in Danaher Co. (NYSE:DHR) by 19.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,676 shares of the conglomerate’s stock after acquiring an additional 268 shares during the quarter. Prosperity Consulting Group LLC’s holdings in Danaher were worth $419,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Envestnet Asset Management Inc. lifted its position in Danaher by 4.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 1,273,800 shares of the conglomerate’s stock valued at $318,259,000 after acquiring an additional 49,761 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its position in Danaher by 42.4% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 115,549 shares of the conglomerate’s stock valued at $28,870,000 after acquiring an additional 34,417 shares in the last quarter. Wrapmanager Inc. lifted its position in Danaher by 14.4% in the 2nd quarter. Wrapmanager Inc. now owns 1,609 shares of the conglomerate’s stock valued at $402,000 after acquiring an additional 203 shares in the last quarter. Allen Investment Management LLC lifted its position in Danaher by 10.4% in the 2nd quarter. Allen Investment Management LLC now owns 1,376,680 shares of the conglomerate’s stock valued at $343,963,000 after acquiring an additional 129,888 shares in the last quarter. Finally, Wealthspire Advisors LLC lifted its position in Danaher by 3.5% in the 2nd quarter. Wealthspire Advisors LLC now owns 4,823 shares of the conglomerate’s stock valued at $1,205,000 after acquiring an additional 165 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Danaher news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now owns 97,983 shares in the company, valued at approximately $27,435,240. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Stock Up 0.6 %

Shares of DHR opened at $274.25 on Friday. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The firm has a market cap of $198.07 billion, a P/E ratio of 46.48, a price-to-earnings-growth ratio of 4.48 and a beta of 0.83. The firm’s 50-day simple moving average is $264.55 and its 200 day simple moving average is $256.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the prior year, the business earned $2.05 EPS. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. On average, analysts forecast that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s payout ratio is presently 18.31%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on DHR. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Danaher in a research report on Friday, September 6th. TD Cowen boosted their price target on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target on the stock. Evercore ISI cut their price target on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Leerink Partners boosted their price target on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.